Acorda Therapeutics (ACOR) Tops Q2 EPS by 14c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Acorda Therapeutics (ACOR) Q2 'Solid', Says Cowen; CVT-301 Development On Track
July 30, 2015 3:46 PM EDTCowen analyst Phil Nadeau reiterated his Outperform rating and $65 price target on Acorda Therapeutics, Inc. (NASDAQ: ACOR) following Q2 revenue and EPS above consensus driven by solid performance from Ampyra.
Nadeau commented, "The U.S. PTO will decide whether to institute... More
